Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?

详细信息    查看全文

• 作者：Ross M. Simon ; Lauren E. Howard ; Stephen J. Freedland ; William J. Aronson ; Martha K. Terris ; Christopher J. Kane ; Christopher L. Amling ; Matthew R. Cooperberg and Adriana C. Vidal
• 刊名：BJU International
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：117
• 期：6
• 页码：897-903
• 全文大小：266K
• ISSN：1464-410X

文摘

To determine if men with adverse pathology but undetectable ultrasensitive (<0.01 ng/mL) PSA are at high-risk for biochemical recurrence (BCR), or if there is a subset of patients at low-risk for whom the benefit of adjuvant radiation therapy might be limited.